Thank you for getting in touch. A member of the Salus team will be in touch with you shortly.
Thank you for reaching out. Someone from the Salus team will be in touch with you shortly — we look forward to learning more.
Salus is a specialist lower mid-market private equity firm, focusing on transatlantic healthcare opportunities across pharma services, life science tools and medtech. Investing primarily across Europe as well as North America where deep scientific expertise, bilateral deal access, hands-on value acceleration and regional & transatlantic expansion create outsized returns.
We invest in lower mid-market healthcare businesses where specialist scientific knowledge, deep sector networks and geographic expansion enable true value acceleration, alongside the hallmarks of what makes lower-mid-market companies attractive investment propositions.
Our mandate deliberately excludes generalist areas such as patient services, primary care or consumer healthcare. Specialist focus is a permanent and defining feature of our strategy, grounded in expertise and experience unique to our team.
All Partners' platform experience reflects a broader strategic thesis, where inter-regional & transatlantic expansion have been a consistent feature across all investments, with originations and exits executed on both sides of the Atlantic.
Asset-light pharma services spanning the full drug development and commercialisation lifecycle. High barriers to entry driven by scientific credibility, regulatory expertise and sticky client relationships.
The enabling infrastructure of modern life science research and diagnostics. Sticky recurring revenue, deep customer integration and strong installed-base effects create durable competitive moats.
Technically differentiated devices and manufacturing services with strong IP, clinical evidence and established reimbursement pathways. Scientific differentiation and regulatory complexity create high and durable barriers to entry.
Selective exposure to specialty and generic pharma niche pharma businesses where scientific differentiation, IP depth or unique market positioning align to our core focus factors, without taking binary product risk.
Technology platforms at the intersection of healthcare operations and data where deep domain expertise and recurring revenue aligns with our broader thesis.
Investing at the intersection of scientific complexity and strategic growth, backing healthcare companies with a scientific edge and scalable growth potential both regionally and transatlantic. Founded with medical expertise and deep private equity experience, the team reflects a rare and deliberate combination of scientific, investment and operational expertise and believes in actively driving hands-on value creation. Intellectual honesty is at the core of what Salus does.